These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 22431509)
21. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893 [TBL] [Abstract][Full Text] [Related]
22. The phosphatase interactor NIPP1 regulates the occupancy of the histone methyltransferase EZH2 at Polycomb targets. Van Dessel N; Beke L; Görnemann J; Minnebo N; Beullens M; Tanuma N; Shima H; Van Eynde A; Bollen M Nucleic Acids Res; 2010 Nov; 38(21):7500-12. PubMed ID: 20671031 [TBL] [Abstract][Full Text] [Related]
23. The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells. Aoki R; Chiba T; Miyagi S; Negishi M; Konuma T; Taniguchi H; Ogawa M; Yokosuka O; Iwama A J Hepatol; 2010 Jun; 52(6):854-63. PubMed ID: 20395008 [TBL] [Abstract][Full Text] [Related]
24. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Li H; Cai Q; Godwin AK; Zhang R Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743 [TBL] [Abstract][Full Text] [Related]
25. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. Pasini D; Bracken AP; Jensen MR; Lazzerini Denchi E; Helin K EMBO J; 2004 Oct; 23(20):4061-71. PubMed ID: 15385962 [TBL] [Abstract][Full Text] [Related]
26. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826 [TBL] [Abstract][Full Text] [Related]
27. Phosphorylation of EZH2 by CDK1 and CDK2: a possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through cell divisions. Zeng X; Chen S; Huang H Cell Cycle; 2011 Feb; 10(4):579-83. PubMed ID: 21278485 [TBL] [Abstract][Full Text] [Related]
28. Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells. Grimaldi G; Christian M; Steel JH; Henriet P; Poutanen M; Brosens JJ Mol Endocrinol; 2011 Nov; 25(11):1892-903. PubMed ID: 21903722 [TBL] [Abstract][Full Text] [Related]
30. The transcriptional repression by NIPP1 is mediated by Polycomb group proteins. Roy N; Van Eynde A; Beke L; Nuytten M; Bollen M Biochim Biophys Acta; 2007; 1769(9-10):541-5. PubMed ID: 17804093 [TBL] [Abstract][Full Text] [Related]
31. The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing. Nuytten M; Beke L; Van Eynde A; Ceulemans H; Beullens M; Van Hummelen P; Fuks F; Bollen M Oncogene; 2008 Feb; 27(10):1449-60. PubMed ID: 17724462 [TBL] [Abstract][Full Text] [Related]
34. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. Friedman J; Cho WK; Chu CK; Keedy KS; Archin NM; Margolis DM; Karn J J Virol; 2011 Sep; 85(17):9078-89. PubMed ID: 21715480 [TBL] [Abstract][Full Text] [Related]
35. Aberrations of EZH2 in cancer. Chase A; Cross NC Clin Cancer Res; 2011 May; 17(9):2613-8. PubMed ID: 21367748 [TBL] [Abstract][Full Text] [Related]
36. Cyclin-dependent kinase 1 (CDK1)-mediated phosphorylation of enhancer of zeste 2 (Ezh2) regulates its stability. Wu SC; Zhang Y J Biol Chem; 2011 Aug; 286(32):28511-9. PubMed ID: 21659531 [TBL] [Abstract][Full Text] [Related]
37. A complex Polycomb issue: the two faces of EZH2 in cancer. Hock H Genes Dev; 2012 Apr; 26(8):751-5. PubMed ID: 22508723 [TBL] [Abstract][Full Text] [Related]
38. Targeting of EZH2 to a defined genomic site is sufficient for recruitment of Dnmt3a but not de novo DNA methylation. Rush M; Appanah R; Lee S; Lam LL; Goyal P; Lorincz MC Epigenetics; 2009 Aug; 4(6):404-14. PubMed ID: 19717977 [TBL] [Abstract][Full Text] [Related]
39. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747 [TBL] [Abstract][Full Text] [Related]
40. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Kirmizis A; Bartley SM; Kuzmichev A; Margueron R; Reinberg D; Green R; Farnham PJ Genes Dev; 2004 Jul; 18(13):1592-605. PubMed ID: 15231737 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]